Wednesday, July 8, 2026

Patent intelligence · US

US 9943545

Stem cell culture media and methods of enhancing cell survival

granted A61KA61K35/14A61PA61P35/00
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 12
Applicant portfolio 53
Patent details — US 9943545
Jurisdiction
US
Status
granted
Grant date
Apr 17, 2018
Expiration
Apr 12, 2038
Claims
55
CPC classes
A61K, A61K35/14, A61P, A61P35/00
View on Google Patents ↗

Quick answer

US 9943545 (Stem cell culture media and methods of enhancing cell survival) is held by Fate Therapeutics, Inc.. Status: granted. Granted Apr 17, 2018. Expires Apr 12, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
55
CPC classes
A61K, A61K35/14, A61P, A61P35/00, A61P35/02, A61P37/00

More from Fate Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Apr 17, 2045

    granted
  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Expires Apr 10, 2045

    granted
  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Expires Mar 27, 2045

    granted
  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Expires Mar 6, 2045

    granted

Frequently asked questions

What is US patent 9943545?

US 9943545 (Stem cell culture media and methods of enhancing cell survival) is held by Fate Therapeutics, Inc.. Status: granted. Granted Apr 17, 2018. Expires Apr 12, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9943545?

Fate Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.

When does US 9943545 expire?

Our index shows an expiration date of Apr 12, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.